Trial Profile

Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alfa (PRX-102) in Patients With Fabry Disease

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegunigalsidase alfa (Primary)
Indications Fabry's disease
Focus Adverse reactions; Registrational
Acronyms BRILLIANCE
Sponsors Chiesi; Protalix Biotherapeutics

Most Recent Events

05 Feb 2026 According to a Chiesi media release, the data from this study were be presented at the 22nd Annual WORLDSymposium.
20 May 2025 Status changed from active, no longer recruiting to completed.
19 Dec 2024 Planned End Date changed from 30 Apr 2025 to 28 Mar 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com